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Abstract 
 
Purpose: To compare imaging changes and pain relief in patients with intra- vs. 
extra-osseous bone metastases treated palliatively with magnetic resonance 
guided high intensity focused ultrasound (MRgHIFU). 
Materials and Methods: 21 patients were treated prospectively with MRgHIFU at 
3 centers. Intra-procedural thermal changes measured on proton resonance 
frequency shift thermometry (PRFS), and Gadolinium T1-weighted (Gd-T1W) 
image appearances after treatment, were compared for intra- and extra-
osseous metastases. Pain scores and analgesic use documented before, and 
up to 90 days after treatment, were used to classify response, and were 
compared between intra- and extra-osseous groups. Gd-T1W changes were 
compared between responders and non-responders in each group. 
Results: Thermal dose volumes were significantly larger in the extra-osseous 
group (p=0.039). Tumor diameter did not change after treatment in either group. 
At Day 30, Gd-T1W images showed focal non-enhancement in 7/9 patients with 
intra-osseous tumors; in patients with extra-osseous tumors, changes were 
heterogeneous.  
Cohort reductions in worst pain scores were seen for both groups, but 
differences from baseline at Days 14, 30, 60 and 90 were only significant for the 
intra-osseous group (p=0.027, p=0.013, p=0.012, p=0.027 respectively). By Day 
30, 67% (6/9) patients with intra-osseous tumors were classified as responders, 
for patients with extra-osseous tumors response rate was 33% (4/12). In neither 
group was pain response indicated by non-enhancement on Gd-T1W. 
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Conclusion: Intra-osseous tumors showed focal non-enhancement by Day 30, 
and patients had better pain response to MRgHIFU than those with extra-
osseous tumors. In this small cohort, post-treatment imaging was not 
informative of treatment efficacy.  
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Introduction 
High Intensity Focused Ultrasound (HIFU) is emerging as a credible option for 
palliating pain from bone metastases(1, 2), a common cause of cancer-related 
morbidity(3). Studies have evaluated the safety and efficacy of HIFU in radiation 
refractory and radiation naïve populations, and shown significant improvements 
in pain, with a low rate of treatment-related adverse events(4-9). The 
mechanism of action may be thermal denervation of the periosteum(2), 
exploiting cortical bone’s high acoustic absorption and low thermal conduction, 
so that targeting it results in energy deposition at the periosteal surface(10). 
This strategy therefore, may be ineffective for extra-osseous metastases, where 
the lack of a cortical barrier may mean that ablative energy is transmitted 
directly into the tumor and misses involved periosteal nerves. Whilst the cortical 
integrity of treated tumors has been noted in a few prior studies(6, 9), pain 
response to HIFU in patients with intra- or extra-osseous bone metastases 
critically remains unexplored. 
HIFU treatments may be guided by MR imaging (MRgHIFU), which allows 
accurate depiction of the target and surrounding anatomy. MRI based 
temperature measurement using a proton resonance frequency shift (PRFS) 
technique is used to monitor treatments(11, 12), where thermal data are 
displayed as color overlays superimposed on anatomical images. Raising tissue 
temperature to ≥56oC for only a few seconds is considered to be ablative(13). 
After treatment, Gadolinium enhanced T1-weighted (Gd-T1W) imaging can 
show non-perfused regions indicative of tissue ablation(14). It may also be used 
to assess outcomes after treatment (6), but the significance of the non-perfused 
volume (NPV) in relation to dose delivered, or to treatment response, is 
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unclear(8, 15). The purpose of this study was to compare imaging changes 
during and after treatment in patients with intra- versus extra-osseous bone 
metastases treated palliatively with MRgHIFU. Any changes were related to 
longitudinal changes in pain scores over 90 days.  
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Materials and Methods 
 
Study Population 
This study interrogated an exploratory end-point in 21 patients with a dominant 
painful bone metastasis participating in a prospective, single arm study 
(NCT01586273)(16). They were treated with MRgHIFU at one of 3 centers, 
after approval from Institutional review boards (REC number: 12/LO/0424, IRB 
code: 2013-04-050). Patients were provided with a study information sheet, 
prior to giving their written informed consent for treatment. All had a proven 
diagnosis of bony metastatic disease arising from a primary solid tumor, and a 
dominant painful metastasis of numerical rating scale (NRS) ≥4/10. Eligibility 
was determined at screening using criteria provided in Table 1. Patient and 
tumor characteristics are provided in Table 2, and classified as either intra-
osseous (cortex intact), or extra-osseous (cortical breach).  
 
Baseline Assessments 
Pre-treatment baseline vital signs and body temperature were recorded, and 
target metastasis NRS pain score documented in a case report form (CRF). 
Global pain was assessed using the Brief Pain Inventory short form (BPI-SF) 
(17). Analgesic use in the 24 hours prior to treatment was also recorded. 
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Treatment delivery 
Treatments were delivered using a Sonalleve HIFU device (Profound Medical, 
Ontario, Canada) with patients positioned within a 3T or 1.5T MR scanner 
(Philips Healthcare, Best, The Netherlands). A dampened Aquaflex gel-pad 
(Parker Laboratories Inc., Fairfield, NJ, USA) ensured optimal acoustic contact 
between their skin and the HIFU device.  
After patients were sedated, MRgHIFU treatments were planned on a patient 
and tumor-specific basis using a series of volumetric treatment ‘cells’ of 4, 8 or 
12 mm diameter(18). For intra-osseous tumors, cells were centered on the 
cortical surface; for extra-osseous tumors, additional cells were positioned 
within its soft tissue component.  
 
Intra-procedural MR Imaging 
T1W Imaging 
3D T1W imaging was acquired over the full extent of the treatment region to 
confirm that the target metastasis lay within the targeting range of the transducer, 
and to allow treatment planning. If patients moved during treatments, the 3D 
T1W imaging was re-acquired to confirm the new patient position, and allow the 
location of prior sonications to be mapped to the new position.  
PRFS Thermometry 
PRFS thermometry was obtained at 3 s intervals before, during, and after each 
sonication to evaluate temperature change in overlying muscle (intra-osseous 
group) and within tumor (extra-osseous group). Sonications were terminated if 
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heating was excessive, occurred outside the target region, or if patient movement 
compromised targeting accuracy. After each sonication, PRFS data were 
reviewed to evaluate the magnitude and extent of thermal change, and 
determined the cooling times required to reduce the risk of unwanted heat build up 
in surrounding tissues.  
Gd-T1W imaging 
On completion of treatments, and after administration of 0.2 ml/kg body weight 
Gd contrast agent, 3D fat suppressed Gd-T1W images were obtained. 
Summary parameters for all sequences are shown in Table E1. 
	
Post treatment assessments 
After treatment, patients’ pain scores for the treated metastasis were recorded 
in the CRF. For 30 days after treatment, patients completed a daily diary to 
record their worst pain score from the treated metastasis, and their analgesic 
consumption. They also completed the BPI-SF at home on Days 7 and 14 after 
treatment, and at Day 30 when they attended a follow-up appointment to 
complete the CRF and undergo MRI. All investigations were repeated on Days 
60 and 90 where possible. Any adverse events (AEs) that occurred after 
recruitment to the study were reported, in accordance with study and 
institutional requirements. 
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Data analysis 
Treatment delivery parameters 
The number, diameter and total volume of treatment cells for each patient were 
recorded. The duration and power of each sonication was noted; their product 
provided the applied acoustic energy of each sonication, whose sum for all 
delivered sonications provided the total acoustic energy for the treatment. 
Treatment time was measured from first exposure to last.  
Thermal changes were measured on PRFS by estimating thermal dose volume, 
calculated as the product of 3 orthogonal maximum dimensions of the 240 
equivalent minutes (EM) at 43oC dose contour(12, 19) (Figure 1). The sum of 
thermal dose volumes for all sonications was the estimate of total thermal dose 
volume for each patient (V240EM). In addition, the maximum temperature 
recorded in the target region during each sonication was used to calculate the 
mean maximum temperature (TM) from all sonications, for each patient.  
Imaging changes after treatment 
T1W images were used to estimate any changes in tumor diameter from 
baseline. Gd-T1W images were used to measure NPV, by drawing regions of 
interest (ROIs) on the immediate post-treatment and Day 30/60/90 images. The 
total NPV was calculated from the product of totaled ROI areas and slice 
thickness. Where no focal NPV was identified, changes were classified as 
Grade 1 change (ill-defined expansion of non-perfused regions) or Grade 2 
change (definite increase in non-perfusion, or reduction in contrast 
enhancement). 
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Treatment Response 
CRF and diary (local) and BPI-SF (global) pain scores at all post-treatment 
time-points were compared with baseline (pre-treatment) scores. The Pain 
Severity Index and the Pain Interference Index were also calculated from the 
BPI-SF(17). A change in analgesic requirement after treatment was assessed 
from the patient diaries and the CRF.  
Treatment response was classified using established criteria(20). Complete 
response (CR) was defined as a BPI-SF worst pain score of zero, without 
increase in analgesic intake. Partial response (PR) was defined as a reduction 
of ≥2 points in worst pain, without analgesic increase; or analgesic reduction of 
≥25%, without increase in worst pain. Pain progression (PP) was an increase of 
≥2 points in worst pain, without analgesic decrease; or analgesic increase of 
≥25%, with worst pain ≤1 point above baseline. No response (NR) applied to all 
other cases. The < or ≥25% change in analgesia was determined by calculating 
the change in morphine equivalent daily dose (MEDD) (21); for non-opioid 
medication where MEDD could not be calculated, the magnitude of dose 
reduction was established through comparison with pre-treatment dose. 
Patients were classified as responders (CR or PR) or non-responders (NR or 
PP) at Days 7, 14, 30, 60 and 90 after treatment.  
Adverse Events 
AEs were classified in accordance with the Clinical Practice Guidelines of the 
Society of Interventional Radiology(22). They were further categorized as 
definitely/probably/possibly/unlikely device-related (from MRgHIFU treatment), 
study-related (from study procedures), or unrelated to treatment. 
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Statistical Analyses 
Statistical analyses were performed using GraphPad Prism software (Version 7, 
San Diego, USA). D’Agostino & Pearson tests for normality were used to select 
parametric or non-parametric tests. A value of p<0.05 was chosen as the 
criterion for statistical significance. 
Baseline patient and tumor characteristics, and treatment delivery parameters 
for intra- and extra-osseous groups, were compared using two-tailed tests for 
unrelated samples; where data were normally distributed, unpaired t-tests were 
used; where they were not, Mann-Whitney tests were used. For each group, 
post treatment changes in pain scores (CRF, diary and BPI-SF) were compared 
using paired t-tests, and a Bonferroni correction for multiple comparisons. 
After treatment, any difference in tumor diameter from baseline was compared 
using paired t-tests for the intra-osseous data, and a Wilcoxon matched-pairs 
signed rank test for the non-normally distributed extra-osseous data. Any 
change in NPV from immediately after treatment to Day 30 was compared using 
paired t-tests after log-transformation of these non-normally distributed data. 
The log-transformed post treatment NPV data were also compared with log-
transformed intra-procedural V240EM data using Pearson’s correlations. Any 
differences in imaging features between intra- and extra-osseous responders 
and non-responders were described qualitatively because the sample sizes of 
these sub-groups were too small to justify the use of statistical tests.  
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Results 
 
Patients and Treatments 
Figure 2 shows the number of treated patients who completed follow-up. Table 
3 gives differences in delivered treatment and PRFS-measured thermal 
parameters between patients with intra-osseous (n=9) and extra-osseous 
(n=12) tumors. Although treatments appeared more extensive in the extra-
osseous group, differences between groups were only significant in the number 
of delivered sonications and the measured thermal dose volume (V240EM). 
 
Imaging changes after treatment 
For both intra- and extra-osseous tumors, mean maximum diameter measured 
on unenhanced T1W imaging was stable after treatment, with no significant 
difference from baseline at any post treatment time-point (Table 3).   
Intra-osseous Group 
A non-perfused volume was recognized immediately after treatment on Gd-T1W 
images in 8 of 9 patients with intra-osseous tumors. In 5/9 (56%), this was seen 
as a rind of non-enhancing tissue on either side of the osseous cortex, with a 
surrounding rim of enhancement at the proximal border of the un-enhanced 
rind. In 3 tumors, ill-defined regions of non-perfusion were seen, and no 
contrast enhancement was evident in one. By Day 30 after treatment, a clear 
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focal region of non-enhancement was present in 7/9 patients (78%) (Figure 3) 
that persisted at Day 60 and 90 in those with follow up. 
NPV measured immediately after treatment in 7/9 patients (mean±SD: 5.5±9.9 
ml, range: 0.1-27.3 ml) showed a strong and significant correlation with V240EM 
measured during treatments (r=0.87, p=0.011). The NPV did not change 
significantly from immediately post treatment to Day 30, (mean±SD: 5.7±8.8 ml, 
range: 1.0-25.3 ml, p=0.25). 
Extra-osseous Group 
All 12 extra-osseous tumors were heterogeneous, with patchy regions of 
contrast enhancement and non-perfused regions of presumed necrosis on 
images acquired prior to the treatment day. These showed no visibly identifiable 
change on the post-treatment scan in 7/12 patients (58%); in 2 there was Grade 
1 change, and in 3 there was Grade 2 change. By Day 30 after treatment, there 
was some evolution of image appearances in the 9 patients with imaging data: 
2 still showed no change from baseline, 4 had Grade 1 change, 2 had Grade 2 
change, and 1 had a re-establishment of pre-treatment enhancement, after 
Grade 1 change had been seen immediately post treatment.  
 
Response to Treatment 
Pain scores recorded on the CRF for the treated tumor in both groups showed 
reduction (Figure 4a,b), but differences from baseline at Days 30, 60 and 90 
were only significant for the intra-osseous Group (p=0.012, p=0.029, p=0.042 
respectively). The same pattern was seen from pain scores recorded in the BPI-
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SF, with significant reductions in worst pain, pain severity index and pain 
interference index at every time-point from Day 14 after treatment only for the 
intra-osseous Group (Figure 5a-f). The daily worst pain scores recorded in the 
patient diaries also showed much earlier onset of pain relief in the intra- vs. 
extra-osseous group, with a >2-point improvement reported 1 day after 
treatment, and 22 days after treatment, respectively (Figure 6a,b). 
6/9 intra-osseous patients (67%) were classified as responders at Day 30, 
compared to 4/12 in the extra-osseous group (33%). The latter also had a 
higher withdrawal rate from the study, with only 50% achieving Day 90 follow-
up, compared to 70% of intra-osseous patients (Figure 7). For both groups of 
patients, there was no clear difference in Gd-T1W imaging changes after 
treatment in those classified as responders or non-responders at Day 30.   
 
Adverse Events (AEs) 
There were no treatment related serious adverse events (SAEs) reported in the 
21 patients. Of 5 AEs related/possibly related to treatment in 4 patients, 4 were 
reports of pain after treatment in intra-osseous patients, and one of temporary 
numbness of the buttock after treatment of a sacral metastasis in an extra-
osseous patient. There were no fractures or skin burns after treatment, although 
Day 30 imaging indicated possible thermal injury to adjacent subcutaneous fat 
tissues in one extra-osseous patient. As expected in this population, the rate of 
AEs unrelated to treatment was higher (42 AEs in 14 patients, mainly relating to 
progression of underlying disease).  
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Discussion  
This study demonstrates significant differences in pain relief for patients with 
intra- vs. extra-osseous bone metastases treated palliatively with MRgHIFU. 
The improvements in pain scores for the treated tumor (measured from the 
CRF) and in global pain (measured from the BPI-SF) seen in both groups 
showed a significant change from baseline at Days 14/30/60/90 only in patients 
with intra-osseous tumors. This was reflected in the patient diaries, which 
showed that changes occurred much earlier, with clinically relevant and 
important improvements(23, 24) being seen within 1 day of treatment. The rapid 
onset of improvement in patients with painful intra-osseous tumors constitutes a 
major advantage of the HIFU technique, but appears harder to achieve in 
patients with extra-osseous tumors. 
The 67% response rate for the intra-osseous patients at Day 30 is comparable 
with other studies that have included heterogeneous populations(4-7, 9, 25). 
Furthermore, of the 3 intra-osseous non-responders at Day 30, one had 
achieved response by Day 60 (sustained at Day 90) whilst the 2 remaining 
patients had each reported 5 and 3 point reductions in focal pain at the treated 
site at Day 60, but both also required >25% increase in analgesia for worsening 
pain in other regions, and were therefore classified as non-responders.  
The lower 33% response rate for the extra-osseous patients at Day 30 did not 
improve at later follow-up. Of the 3 patients classified as non-responders at Day 
90, 2 only ever experienced a 1-point reduction in pain score, without a change 
in analgesia, whilst 1 patient had both increased pain scores and increased 
analgesia, making all 3 true non-responders. The high rate of withdrawal from 
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the study (50% by Day 90) because of disease progression is testament to the 
fact that these were patients with end-stage disease. Consequently, there were 
numerous adverse events unrelated to treatment reported in this group.  
If HIFU thermally denervates the periosteum(2, 26), it is unsurprising that better 
response rates were seen in the intra-osseous group. Furthermore, as the 
treatments delivered to patients with the larger extra-osseous tumors were not 
significantly more extensive than those delivered to the smaller intra-osseous 
tumors, an insufficient proportion of the soft tissue tumors may have been 
targeted to elicit a response, either from a de-bulking effect, or from alterations 
in the release of pro-inflammatory signaling molecules(26, 27). A larger relative 
extent of thermal dose volume may be needed to achieve pain control in these 
soft tissue tumors. Whilst more aggressive treatments are technically feasible, 
they also risk a greater rate of adverse events. However, the aim of achieving 
local tumor control, as well as pain palliation, has already been highlighted as a 
research priority for MRgHIFU of painful bone metastases(1). 
In the intra-osseous patients, thermal neurolysis was probably achieved, given 
clear regions of focal non-enhancement (NPV) were seen immediately after 
treatment in 5/9 patients, and by Day 30 in 7/9 cases. The NPV was 
significantly correlated with thermal dose volumes (V240EM), but did not translate 
to an indication of treatment response.  The small sample size, or the potential 
confounding effects of response classification may explain this. Alternatively, it 
may be that periosteal ablation is achieved regardless of visible soft tissue 
damage. This re-inforces previous studies where NPV was unrelated to pain 
score(15), and did not differ between responders and non-responders(8).  
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These results suggest that post treatment imaging, even using contrast-
enhanced techniques, may not be informative about treatment efficacy for pain 
palliation of bone metastases. It can also only play a very limited role in 
ensuring patient safety, given that the opportunity to modify treatments has 
passed. It might serve a purpose in early recognition of complications, e.g. a 
large immediate post treatment NPV involving adjacent muscle in 1 intra-
osseous patient could have prompted pro-active, early referral for physiotherapy 
to reduce muscle stiffness. However, this could also have been recognized 
during treatment because of the high intra-procedural V240EM. Thus PRFS data 
may potentially help flag the likelihood of collateral tissue damage at a time 
when treatments could still be modified or curtailed. Removing the requirement 
for post treatment imaging assessments would reduce the burden of imaging 
appointments on patients, and spare them repeat administrations of contrast 
agents at a time when use of these agents is increasingly scrutinized. It would 
also reduce the resource requirement for institutions delivering these 
treatments. 
The main limitation of this study was the small sample size in each group, 
caused by difficulties in recruiting sufficient suitable patients within a reasonable 
timescale, and high rates of study withdrawal. A potential source of bias in the 
findings was that the patients in each group were not matched, and the extra-
osseous patients may have had more advanced disease. Response relative to 
ablative thermal dose per tumor volume and length of destroyed cortex needs to 
be established in these patients. There was also no mechanism for separating 
analgesic use for pain in a target tumor from pain in non-target regions, 
potentially confounding response assessment in some cases. In addition, the 
	 	 19	
estimated V240EM was only an approximation of thermal dose volume, chosen 
because it could be quickly and easily obtained on the Sonalleve console as 
treatments progress. More accurate and robust methods for calculating thermal 
dose volume after treatment completion already exist, and could potentially be 
made available in a more timely fashion. 
This study documents differences in MRgHIFU treatments delivered to patients 
with intra- and extra-osseous bone metastases. Response rates for patients 
with intra-osseous tumors were considerably better than for those with extra-
osseous ones, who may require more aggressive treatments to achieve pain 
control. Imaging changes differed between the groups, but did not indicate 
treatment response. Follow-up scanning after treatment might therefore only be 
required for assessing disease progression or adverse events, rather than for 
monitoring on-going treatment efficacy.  
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Tables and Figures 
Table 1: Eligibility Criteria 
Inclusion	criteria	 Exclusion	criteria	
Prior	to	enrolment:	Adult	≥18	years,	 Metastasis	is	from	primary	bone	tumor,	lymphoma,	myeloma	or	leukemia	Patient	capable	of	communication	and	informed	consent	 Communication	barrier	present	Weight	<	140	kg	 Patient	enrolled	in	conflicting	clinical	study		Radiologic	evidence	of	bone	metastases	from	any	solid	tumor	 Pain	related	to	target	metastasis	mainly	due	to	fracture,	impending	fracture,	or	to	spinal	cord	compression	Dominant	painful	bone	metastasis	(NRS≥4),	either	refractory	to	standard	of	care	treatment,	or	standard	of	care	contra-indicated	or	refused	by	patient	
Target	tumor	located	in	skull,	spine	(excluding	sacrum),	or	ribs	and	sternum	(unless	exposure	to	lung	can	be	avoided)	Patient	has	been	on	stable	pain	medication	for	≥1	week	before	proposed	HIFU	treatment	 Need	for	surgical	stabilization	in	case	of	impending	fracture	(lytic	tumor	in	weight-bearing	bone	larger	than	50%	of	bone	diameter)	Pain	localized	to	target	metastasis,	or	referred	pain	arising	from	it	 Pregnancy	Patient	has	≤3	painful	bone	metastases	 Prior	surgery	or	minimally	invasive	treatment	of	target	tumor	Planned	HIFU	treatment	date	≥4	weeks	from	last	local	treatment	of	target	metastasis	 Clinically	relevant	medical	history	that	could	compromise	patient	safety	
At	screening:	Intended	target	metastasis	accessible	for	HIFU	 Contra-indications	to	MRI,	MR	contrast	media,	or	to	sedation	Target	tumor	diameter	≤8cm	 Scar	along	proposed	beam	path		Intended	target	tumor	visible	by	non-contrast	enhanced	MR	imaging	 Internal	or	external	fixation	device	along	proposed	beam	path,	or	at	target	Distance	between	tumor	and	skin	≥1cm	 Patient	unable	to	tolerate	required	position	for	treatment		 Target	tumor	<3cm	from	critical	structure	along	proposed	beam	path,	or	<1cm	orthogonal	to	beam	path		 Target	in	contact	with	hollow	viscera		
 
Table 1: Eligibility criteria: initial criteria refer to patients’ suitability for enrolment 
in the trial, before consent for screening investigations. After screening to 
confirm patients’ suitability for treatment, further eligibility criteria were applied 
prior to their inclusion. 
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Table 2: Patient and tumor characteristics 
	 	 Intra-osseous	
Group	
Extra-osseous	
Group	
Patients	 	 	n	(%)	 9	(43%)	 12	(57%)	Sex	 3	male	(33%)	6	female	(67%)	 8	male	(67%)	4	female	(33%)	Age	(years)	 52.6±9.6	 58.1±11.3	
Primary	tumor	site	 	 	Breast		 6	(67%)	 2	(17%)	Liver	 -	 4	(33%)	Lung	 1	(11%)	 3	(25%)	Renal	 1	(11%)	 2	(17%)	Colorectal	 -	 1	(8%)	Eccrine	 1	(11%)	 -	
MRgHIFU	Treatment	Site	 	 	
Pelvis	 5	(56%)	 8	(67%)	
Ribs	 2	(22%)	 1	(8%)	
Humerus	 1	(11%)	 1	(8%)	
				Femur	 1	(11%)	 1	(8%)	
				Sacrum	 -	 1	(8%)	
Prior	EBRT	to	target	metastasis	 9	(100%)	 12	(100%)	
					8	Gy	1#	 3	(33%)	 2	(17%)	
20	Gy	5#	 2	(22%)	 1	(8%)	
					30	Gy	10#	 3	(33%)	 1	(8%)	
					High	dose	>30	Gy,	or	multiple	treatments	 1	(11%)	 8	(67%)	
					Responder	to	prior	EBRT?	(CR	or	PR)	 3	(33%)	 6	(50%)	
Baseline	pain	from	target	metastasis	 	 	
				NRS	4-6:	Moderate	pain	 3	(33%)	 5	(42%)	
				NRS	7-10:	Severe	pain	 6	(67%)	 7	(58%)	
	
	
Table 2: Characteristics of n=21 patients treated with MRgHIFU, all of whom 
had received prior radiotherapy to the target tumor. NB: Intra-osseous lesions 
had intact bone cortex along the entire length of the tumor, with no visible 
periosteal involvement; extra-osseous lesions had clear cortical breach with 
visible periosteal involvement with tumor. EBRT= external beam radiotherapy, 
CR=complete response, PR=partial response. 
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Table 3: Differences in treatment parameters and tumor diameter between 
groups. 
	 	 Intra-osseous	
Group	
Extra-osseous	
Group	
Difference	
Delivered	treatment	
parameters	 	 	 	Depth	of	target	(mm)	 35.9±17.1	 36.9±16.3	 p=0.9	n	sonications	 15±5	 29±15	 p=0.022	Use	of	12	mm	diameter	cells	 1	patient	 4	patients	 	Treatment	volume	(ml)	 12.1±13.3	 16.4±12.0	 p=0.21	Treatment	time	(minutes)	 70.6±28.2	 89.4±42.0	 p=0.25	Mean	power	per	sonication	(W)	 69.8±29.9	 85.2±46.8	 p=0.41	Total	energy	of	treatment	(kJ)	 23.5±16.8	 51.9±49.3	 p=0.17	
Measured	thermal	parameters	 	 	 	V240EM	(ml)	 5.4±9.9	range:	0.3-31.2		 13.9±19.1	range:	2.4-62.7	 p=0.039	TM	(oC)	 62.2±5.9	 60.6±4.7	 p=0.51	
Tumor	Diameter	 	 	 	At	baseline	(mm)		 38.9±12.8	 55.7±14.9	 p=0.012	Significance	of	change	in	lesion	diameter	from	baseline	(*)	 	 	 	At	Day	30	 p=0.83	 p=0.13	 	At	Day	60	 p=0.96	 p=0.47	 	At	Day	90	 p=0.34	 p=0.63	 	
	
	
Table 3: Differences in characteristics and treatment parameters for patients 
with intra- versus extra-osseous tumors. Baseline tumor diameter, and the lack 
of significant change after treatment are also indicated (*p-values uncorrected 
for multiple time-point comparisons). Unless otherwise specified, values 
provided are mean±standard deviation (SD) values. 
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Supplementary Table E1 
Parameter	 T1W	 PRFS	 Gd-T1W	TR	(ms)	 3.5	 25	 5.4	TE	(ms)	 2.3	 16	 2.6	FA	(o)	 7	 18	 12	Fat	suppression	 -	 ProSet	 SPAIR	Frequency	offset	(Hz)	 -	 -	 220	EPI/TFE	factor	 -	 11	 18	Voxel	size	(mm3)	 1.25	x	1.75	x	1.25	 2.1	x	2.1	x	7.0	 1.5	x	1.5	x	3.0	FOV	(mm)	 240	x	320	x	140	 400	x	300	x	7	each	stack	 220	x	220	x	105		NSA	 2	 2	 1	Number	slices	 112	 4	 70	Scan	duration	min:sec	 *	2:30		-	3:10	 $	0:03	 1:55	
 
Supplementary Table E1: Summary of acquired sequence parameters at one 
site using a 3T Achieva system. Comparable sequence parameters were 
implemented at the other 2 sites, one of which used a 3T system and the other 
used a 1.5T system. NB: * Scan duration was influenced by the amount of 
oversampling required to avoid wrap artefacts, $ Images updated every 3 s 
(dynamic scan time); total acquisition time was determined by number of frames 
of imaging (dynamics) acquired. 
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Figure 1 
 
Figure 1: V240EM estimates overlaid on T1W imaging acquired for treatment 
planning in a patient with an intra-osseous tumor. The white line (arrowed) 
represents the 240EM at 43oC thermal dose contour in (a) the axial, and (b) the 
coronal planes. The colored pixels (scale given in c) show the thermal dose in 
equivalent minutes (EM) within this contour. The product of the 3 largest 
orthogonal dimensions of the 240EM contour was used to estimate the thermal 
dose volume of each sonication. The total of these volumes was recorded as 
the total thermal dose volume (V240EM) for each patient. NB: the orange contour 
represents the 30EM thermal dose contour, and the yellow ellipses show the 
positions of planned cells.  
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Figure 2 
 
Figure 2: Numbers of patients initially enrolled in the study and who 
subsequently progressed to treatment and attended for follow-up. Of the 9 
patients who failed to complete Day 90 follow-up, 5 were withdrawn from the 
study due to adverse events unrelated to treatment, 3 were referred to other 
interventions (radiotherapy), and 2 chose to withdraw from the study due to 
declining health. 
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Figure 3 
 
Figure 3: Example Gd-T1W image appearances 30 days after treatment. A 
clear focal region of non-enhancement (arrowed) was seen either side of the 
bony cortex for intra-osseous tumors, shown in (a) a 36 year old male with 
metastatic lung cancer, and (b) a 45 year old female with metastatic breast 
cancer. In both cases, a thin rim of enhancing tissue was also seen at the 
proximal border of the region of non-enhancement. 
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Figure 4 
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Figure 4: Pain scores recorded in the CRF for the treated tumor for (a) 9 
patients in the intra-osseous group and (b) 12 patients in the extra-osseous 
group. In each graphic, the horizontal lines show the mean±SD scores, and a 
discrete marker shape is used to show the individual score for each patient at 
each time-point. At Days 30, 60 and 90 after treatment, scores were 
significantly lower than pre-treatment (Pre Tx) for the intra-osseous group, but 
not for the extra-osseous group. The displayed p-values have been corrected 
for multiple comparisons; p>1* indicates that the uncorrected p-value was 
already >0.34. 
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Figure 5 
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Figure 5: BPI-SF pain metrics for (a,c,e) intra-osseous and (b,d,f) extra-
osseous groups. Worst pain, pain severity index, and pain interference index 
were all significantly improved from Day 14 after treatment for the intra-osseous 
group, but not for the extra-osseous group.  Horizontal lines show the mean±SD 
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scores, and the discrete marker shapes show individual scores for each patient. 
Displayed p-values have been corrected for multiple comparisons; p>1* 
indicates that the uncorrected p-value was >0.20. 
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Figure 6 
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Figure 6: Mean±SD 24-hour worst pain scores recorded in the patient diaries 
for (a) the intra-osseous group and (b) the extra-osseous group. Day -1 was the 
score recorded on the treatment day before treatment, whilst Day 0 was the 
score recorded on the same day after treatment. The dotted lines show the 
mean pre-treatment and Day 30 scores. A >2-point improvement in pre-
treatment scores was seen 1 day after treatment for the intra-osseous group, 
but not until Day 22 for the extra-osseous group. The pre-treatment score for 
the extra-osseous group appears artificially low in comparison with baseline 
CRF and BPI-SF scores. However, even if the post-treatment score had been 
used as the baseline, scores improved more gradually in this group, compared 
to the intra-osseous patients. 
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Figure 7 
 
Figure 7: Treatment response classification for (a) intra-osseous and (b) extra-
osseous groups. The proportion classified as responders at each time-point is 
shown by the dark and light green segments, which indicate a complete 
response (CR), or a partial response (PR) respectively. The non-responders are 
shown in blue (NR: no response), and in red (PP: pain progression). The grey 
segments show the patients who did not have follow-up data at each time-point 
(ND: no data). These show higher response rates for the intra-osseous group at 
every time-point, even though 2 patients initially had a flare of increased pain 
(which subsequently resolved). More of the intra-osseous group completed 
follow-up compared to the extra-osseous group (where 2 patients did not 
complete Day 7, and 50% were withdrawn by Day 90). 
 
